HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+32.75%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.77B
AUM Growth
+$2.77B
(+11%)
Cap. Flow
-$19.9M
Cap. Flow
% of AUM
-0.72%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
73
New
19
Increased
16
Reduced
15
Closed
17
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$140M |
| 2 |
Teleflex
TFX
|
$117M |
| 3 |
Hologic
HOLX
|
$86.4M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$80.8M |
| 5 |
Envista
NVST
|
$75.5M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$134M |
| 2 |
Edwards Lifesciences
EW
|
$115M |
| 3 |
Merck
MRK
|
$93.2M |
| 4 |
Baxter International
BAX
|
$90.3M |
| 5 |
Intuitive Surgical
ISRG
|
$89.7M |
Sector Composition
| 1 | Healthcare | 93.28% |
| 2 | Technology | 1.69% |
| 3 | Industrials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Labcorp
LH
$23.1B
| $144M | 5.15% | 852,900 +379,420 | +80% | +$64.2M |
|
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $140M | 4.99% | +372,770 | New | +$140M |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $138M | 4.91% | 1,170,080 +216,260 | +23% | +$25.4M |
|
|
4
Hologic
HOLX
$14.9B
| $129M | 4.59% | 2,464,040 +1,654,470 | +204% | +$86.4M |
|
|
5
Teleflex
TFX
$5.59B
| $117M | 4.16% | +309,620 | New | +$117M |
|
6
HCA Healthcare
HCA
$94.5B
| $109M | 3.88% | 736,670 +329,440 | +81% | +$48.7M |
|
7
Johnson & Johnson
JNJ
$427B
| $100M | 3.58% | 687,960 +344,420 | +100% | +$50.2M |
|
8
Madrigal Pharmaceuticals
MDGL
$9.76B
| $99.2M | 3.54% | 1,088,310 +57,090 | +6% | +$5.2M |
|
|
9
Aurinia Pharmaceuticals
AUPH
$1.58B
| $97.7M | 3.48% | 4,820,330 +3,987,960 | +479% | +$80.8M |
|
10
Medtronic
MDT
$119B
| $96.2M | 3.43% | 847,700 +312,950 | +59% | +$35.5M |
|
11
UnitedHealth
UNH
$281B
| $87.8M | 3.13% | 298,720 -94,810 | -24% | -$27.9M |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $86.7M | 3.09% | 806,864 -686,616 | -46% | -$73.8M |
|
|
13
Envista
NVST
$3.52B
| $84.4M | 3.01% | 2,846,150 +2,546,150 | +849% | +$75.5M |
|
14
Zimmer Biomet
ZBH
$21B
| $66.9M | 2.39% | 447,012 -276,358 | -38% | -$41.4M |
|
|
XENT
15
DELISTED
Intersect ENT, Inc
XENT
| $63.2M | 2.25% | 2,536,760 -4,870 | -0.2% | -$121K |
|
16
Haemonetics
HAE
$2.63B
| $61.9M | 2.21% | 538,962 +327,292 | +155% | +$37.6M |
|
17
CONMED
CNMD
$1.68B
| $59.9M | 2.14% | 536,020 +109,110 | +26% | +$12.2M |
|
|
BLUE
18
DELISTED
bluebird bio
BLUE
| $59.7M | 2.13% | 680,430 +173,340 | +34% | +$15.2M |
|
19
Becton Dickinson
BDX
$55.3B
| $58.7M | 2.1% | +216,000 | New | +$58.7M |
|
20
Humana
HUM
$36.5B
| $57.3M | 2.05% | 156,430 +86,360 | +123% | +$31.7M |
|
21
Bristol-Myers Squibb
BMY
$96B
| $53.9M | 1.92% | 840,000 -277,710 | -25% | -$17.8M |
|
22
Danaher
DHR
$147B
| $50.5M | 1.8% | 328,970 -358,010 | -52% | -$54.9M |
|
|
23
Intuitive Surgical
ISRG
$170B
| $49.4M | 1.76% | 83,550 -151,655 | -64% | -$89.7M |
|
|
ABMD
24
DELISTED
Abiomed Inc
ABMD
| $48.9M | 1.74% | +286,710 | New | +$48.9M |
|
|
25
Merck
MRK
$210B
| $48.5M | 1.73% | 533,210 -1,025,080 | -66% | -$93.2M |
|